Boston, MA 06/04/2013 (wallstreetpr) – The share prices of Chelsea Therapeutics International Limited (NASDAQ:CHTP) had surged by 22.28 percent to close at $2.36 per share for the end of last trading session on Monday. The shares of the pharmaceutical company had been trading in the range of $1.95 to $2.49 per share during the day. With the recent surge in prices, the shares of Chelsea Therapeutics International Limited (NASDAQ:CHTP) had hit new 52 week high price level at $2.49 per share and the 52 week low price level of the company is at $0.70 per share.
Chelsea Therapeutics International Limited (NASDAQ:CHTP) is in the development stage of the sector and is engaged in the research, development and commercialization of treatment therapies for wide range of human diseases. In the recently held Annual Deutsche Bank Health Conference, Chelsea Therapeutics International Limited (NASDAQ:CHTP) had presented a corporate update and an introduction to the development program of their product candidate Northera TM (droxidopa).
Northera is one of the leading product candidates of Chelsea Therapeutics International Limited (NASDAQ:CHTP) which is presently in the Phase III of development stage. The drug is aimed at the treatment of neurogenic orthostatic hypotension in patients with Parkinson’s disease, pure autonomic failure and multiple system atrophy.
The shares of Chelsea Therapeutics International Limited (NASDAQ:CHTP) had witnessed heavy trading volumes on Monday with nearly 6 million shares being exchanged hands, while the average trading volume for the company is at 552,559 share per day. The company presently holds 67.02 million shares outstanding in the market with 38 percent institutional ownership.
